# Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05): CATALYSIS

> **NCT01917552** · PHASE3 · RECRUITING · sponsor: **Asan Medical Center** · enrollment: 870 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** capecitabine

## Key facts

- **NCT ID:** NCT01917552
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2013-08-19
- **Primary completion:** 2026-08-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 870 (ESTIMATED)
- **Last updated:** 2024-02-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01917552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01917552, "Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05): CATALYSIS". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01917552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*